Literature DB >> 307353

Influenzal vaccine response in systemic lupus erythematosus.

R Brodman, R Gilfillan, D Glass, P H Schur.   

Abstract

The response of patients with systemic lupus erythematosus and normal subjects to systemic immunization and boosting with influenza A vaccines was studied. Symptoms after vaccination were somewhat more frequent in the patients than in the normal subjects; however, all symptoms were minor and no major flare of illness occurred. No significant induction or increase of pre-existing autoantibodies among the patients was detected after vaccination. The immunogenecity of the vaccinations, as assessed by antibody titers, was similar in the patient and control groups. No correlation between serologic response to influenzal antigens and HLA was found. Thus, in this group of patients with systemic lupus erythematosus, who were either in remission or had mild-to-moderate disease activity, killed influenzal vaccination caused no apparent worsening of disease activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 307353     DOI: 10.7326/0003-4819-88-6-735

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  21 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.

Authors:  A Holvast; A Huckriede; J Wilschut; G Horst; J J C De Vries; C A Benne; C G M Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

Review 3.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

4.  Heptavax-B in pediatric dialysis patients: effect of systemic lupus erythematosus. Chesapeake Pediatric Nephrology Study Group.

Authors:  M M Moxey-Mims; K Preston; B Fivush; F McCurdy
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 5.  Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  L Turner-Stokes; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-07       Impact factor: 19.103

6.  Properties of the ribosomal P2 protein autoantigen are similar to those of foreign protein antigens.

Authors:  K Elkon; E Bonfa; R Llovet; W Danho; H Weissbach; N Brot
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

7.  Antibody response after influenza immunization in renal transplant patients receiving cyclosporin A or azathioprine.

Authors:  K L Huang; J A Armstrong; M Ho
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen.

Authors:  A B Gottlieb; R G Lahita; N Chiorazzi; H G Kunkel
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

Review 9.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

10.  B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis.

Authors:  C G Kallenberg; P C Limburg; C Van Slochteren; F J Van der Woude; T H The
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.